Engineered t cells take on deadly brain cancers

NCT ID NCT04099797

First seen Jun 26, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This early-phase trial tests a new type of immune therapy for people with certain aggressive brain tumors, including DIPG and high-grade glioma. The treatment uses the patient's own T cells, which are modified in the lab to recognize a protein called GD2 on cancer cells and to produce a signal that helps them survive longer. The cells are given first through a vein and then directly into the fluid around the brain. The main goal is to find the safest dose and see if the cells can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
C7R-GD2.CART cells (a type of modified immune cell)
What this could lead to
If it works, this could point toward a new treatment option for aggressive brain tumors like DIPG and high-grade glioma.
What could go wrong
This is an early phase 1 trial with only 56 participants, so it is too soon to know if it will be effective. Risks include side effects from the cell infusion and chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID/RHABDOID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Texas Children's Hospital

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.